经导管主动脉瓣植入术研究进展

刘坤; 李裕舒; Emmanuel Chorianopoulos; Florian Leuschner

doi:10.13201/j.issn.1001-1439.2016.10.001

经导管主动脉瓣植入术研究进展

- 1 华中科技大学附属协和医院心内科华中科技大学同济医学院心血管病研究所(武汉, 430022);
- 2 Innere Medizin Ⅲ:Kardiologie, Angiologie und Pneumologie, Medizinische Klinik, Universitäts Klinikum Heidelberg

详细信息

通讯作者: 刘坤,E-mail:liukun@hust.edu.cn

中图分类号: R542.5

收稿日期: 2016-09-06

Progress of transcatheter aortic valve replacement

- 1 Department of Cardiology, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China;
- 2 Innere Medizin Ⅲ:Kardiologie, Angiologie und Pneumologie, Medizinische Klinik, Universitäts Klinikum Heidelberg

More Information

Corresponding author: LIU Kun, E-mail: liukun@hust.edu.cn

Received Date: 06 September 2016

摘要

摘要: 随着人口结构的老龄化,主动脉瓣狭窄等心脏瓣膜病的发病率呈上升趋势。近年来,一种新的心血管介入治疗技术——经导管主动脉瓣植入术(TAVR)被临床试验证实其疗效,已被指南推荐治疗不能耐受外科手术或手术高危的严重主动脉瓣狭窄患者。随着新一代经导管植入心脏瓣膜系统的开发和TAVR术临床实践的深入,TAVR手术并发症将得到有效的控制,其适应证不断拓宽,给心脏瓣膜病的治疗带来新的突破。
- 主动脉瓣狭窄 /
- 导管 /
- 植入
Abstract: With aging,aortic-valve stenosis shows an increasing tendency of morbidity.In recent years,a novel interventional technique-transcatheter aortic valve replacement(TAVR)has been validated the efficacy through clinical trials and recommended by the guidelines to treat surgery inoperable or high-risk patients with severe aortic stenosis.With the development of new transcatheterheart valves,TAVR can make breakthroughs on treatment by lowering complications and broadening indications.
- aortic valve stenosis /
- catheter /
- replacement

HTML全文

参考文献(11)

[1]	OTTO C M,PRENDERGAST B.Aortic-valve stenosis--from patients at risk to severe valve obstruction[J].N Engl J Med,2014,371:744-756.
[2]	LUNG B,BARON G,BUTCHART E G,et al.A prospective survey of patients with valvular heart disease in Europe:The Euro Heart Survey on Valvular Heart Disease[J].Eur Heart J,2003,24:1231-1243.
[3]	PELLIKKA P A,SARANO M E,NISHIMURA R A,et al.Outcome of 622adults with asymptomatic,hemodynamically significant aortic stenosis duringprolonged follow-up[J].Circulation,2005,111:3290-3295.
[4]	LEON M B,SMITH C R,MACK M,et al.Transcatheteraortic-valve implantation for aortic stenosis in patientswho cannot undergo surgery:the PARTNER trial investigators[J].N Engl J Med,2010,363:1597-1607.
[5]	SMITH C R,LEON M B,MACK M J,et al.Transcathetervs surgical aortic-valve replacement in highrisk patients:the PARTNER trial investigators[J].N Engl J Med,2011,364:2187-2198.
[6]	NISHIMURA R A,OTTO C M,BONOW R O,et al.2014 AHA/ACC guideline for the management of patients with valvular heart disease:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].Circulation,2014,129:2440-2492.
[7]	LEON M B,SMITH C R,MACK M J,et al.Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients[J].N Engl J Med,2016,374:1609-1620.
[8]	MACK M J,LEON M B,SMITH C R,et al.5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis(PARTNER 1):a randomised controlled trial[J].Lancet,2015,385:2477-2484.
[9]	KAPADIA S R,LEON M B,MAKKAR R R,et al.5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis(PARTNER 1):a randomised controlled trial[J].Lancet,2015,385:2485-2491.
[10]	KASEL A M,CASSESE S,BLEIZIFFER S,et al.Standardized imaging for aortic annular sizing:implications for transcatheter valve selection[J].JACC Cardiovasc Imaging,2013,6:249-262.
[11]	TAYLOR J.ESC/EACTS Guidelines on the management of valvular heart disease[J].Eur Heart J,2012,33:2371-2372.